Diabetes|2026|Ragozzino G et al.
PMID: 42160524
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: Semaglutide is a GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. Its clinical effects are well established, but the underlying mechanisms remain unclear. This study aims to use computational modelling to generate hypoth…
OBJECTIVES: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. DESIGN: Nested population-based case-control study. SETTING: Nationwide healthcare registries with data on dispensed medications and healthcare diagn…
INTRODUCTION: Within the cardiovascular-kidney-metabolic syndrome (CKM) framework, semaglutide has demonstrated benefits beyond glycemic control and weight loss in clinical trials. However, most real-world studies in type 2 diabetes (T2D) have limite…
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, exhibits significant neuroprotective effects in stroke and neurodegenerative diseases. However, the antiinflammatory and barrier-protective effects of semaglutide and the mechanisms…
Glucagon-like peptide-1 receptor agonists (GLP-1s), including semaglutide and tirzepatide, are rapidly transforming weight management practices and public discourse surrounding bodies, health, and responsibility. Although biomedical outcomes of GLP-1…
The year 2025 saw major advances in gastroenterology and hepatology. Having long been overshadowed by other chronic viral hepatitis, Hepatitis D now benefits from new therapeutic options, including bulevirtide, offering markedly improved clinical pro…
INTRODUCTION: Familial partial lipodystrophy type 2 (FPLD2) is a rare autosomal dominant laminopathy caused by LMNA gene variants. It is characterized by progressive gluteofemoral lipoatrophy and severe metabolic derangements, including insulin resis…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1s) have been associated with reduced atrial fibrillation (AF) incidence. Although weight loss is a known benefit of GLP-1 therapy and an established AF risk modifier, it remains unclear whet…
BACKGROUND: Obesity remains a major public health concern in the United States, with increasing demand for body-contouring procedures following significant weight loss. Appalachia-a region characterized by limited healthcare access and a high prevale…
Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation worldwide. It is a multifactorial condition with diverse aetiologies, in which metabolic and nutritional factors are increasingly recognised, whereas pharmac…
Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzuma…
AIM: PIONEER REAL Saudi Arabia investigated real-world clinical outcomes associated with the use of once-daily oral semaglutide in adults with type 2 diabetes (T2D). MATERIALS AND METHODS: This was a 34- to 44-week multicentre, prospective, open-labe…
Developed to treat type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with a reduced risk of cardiovascular events in high-risk patients with diabetes, and later in obese patients with cardiovascular disease w…
Dercum's disease (DD) is a rare chronic disorder characterized by painful subcutaneous lipomas, mostly affecting overweight or obese middle-aged women. The etiology remains unclear, and evidence for medical treatments is limited. Surgical approaches…
BACKGROUND: This study aimed to assess the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonist use and interest in using medications for weight loss among adults (≥ 18 years) in Great Britain. METHODS: Nationally representative household s…
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30%-40% of youth with obesity and lacks approved pharmacologic therapies. In this single-center retrospective case series at a tertiary care safety-net children's hospital, we e…
BACKGROUND AND PURPOSE: Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite…